| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d48685c5fffe9de942228601e5f37a3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2720-12034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2720-12032 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8b25081307cbe09bcca6244e7920857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb032e58c2dd294fa3e53664346f9353 |
| publicationDate |
2010-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010247622-A1 |
| titleOfInvention |
Treatment regime for proliferative disorders |
| abstract |
Provided herein are methods for treating or ameliorating a proliferative disorder in a subject. The method contains the steps of administering to the subject one dose of an immunosuppressive agent followed by administering to the subject one to five doses of a reovirus. The immunosuppressive agent is administered to the subject at least about 72 hours prior to administration of the reovirus. Also provided herein are methods for treating or ameliorating a proliferative disorder in a subject including the steps of administering to the subject an oncolytic virus and a B-cell modulating agent. Also provided are kits and pharmaceutical compositions containing an oncolytic virus and at least one B-cell modulating agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10736962-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980850-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011086005-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10512662-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017122946-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11541087-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253560-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426460-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10639366-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10548930-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10765711-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11242509-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11285209-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11234968-B2 |
| priorityDate |
2007-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |